Scholarlink

Background <p>The overall incidence of pituitary apoplexy among patients with pituitary adenoma ranges from 0.6% to 7.0%, although many cases likely go undiagnosed. Several precipitating factors have been identified, and a small number of case reports have suggested an association between immune checkpoint inhibitors and pituitary apoplexy, particularly in patients with preexisting adenoma. Moreover, the safety of immune checkpoint inhibitor rechallenge remains uncertain.</p> Case presentation <p>The patient was a 71-year-old woman with a recurrence of metastatic primary rectal melanoma. A pituitary tumor had been identified before initiation of systemic therapy. Following the second cycle of nivolumab plus ipilimumab, the patient developed headache, nausea, and vomiting, followed by decreased serum thyroid-stimulating hormone, adrenocorticotrophic hormone, and luteinizing hormone levels. These findings were consistent with evolving hypopituitarism. Contrast-enhanced magnetic resonance images revealed hemorrhage in the pituitary adenoma, suggesting pituitary apoplexy. Eight months after discontinuation of nivolumab plus ipilimumab, disease progression was noted, and nivolumab monotherapy was resumed. There was no recurrence of pituitary apoplexy during six cycles of nivolumab.</p> Conclusions <p>This case highlights that pituitary apoplexy can occur temporally after nivolumab plus ipilimumab treatment in patients with preexisting pituitary adenoma. Importantly, nivolumab monotherapy rechallenge under close monitoring may be feasible without recurrence of pituitary apoplexy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Nivolumab rechallenge after pituitary apoplexy associated with nivolumab plus ipilimumab in a patient with pituitary adenoma and rectal melanoma: a case report and literature review

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月19日

查看全文
  • Chiaki Imai,
  • Masashi Uchida,
  • Koji Takahashi,
  • Izumi Ohno,
  • Yuichi Takiguchi,
  • Itsuko Ishii

摘要

Background

The overall incidence of pituitary apoplexy among patients with pituitary adenoma ranges from 0.6% to 7.0%, although many cases likely go undiagnosed. Several precipitating factors have been identified, and a small number of case reports have suggested an association between immune checkpoint inhibitors and pituitary apoplexy, particularly in patients with preexisting adenoma. Moreover, the safety of immune checkpoint inhibitor rechallenge remains uncertain.

Case presentation

The patient was a 71-year-old woman with a recurrence of metastatic primary rectal melanoma. A pituitary tumor had been identified before initiation of systemic therapy. Following the second cycle of nivolumab plus ipilimumab, the patient developed headache, nausea, and vomiting, followed by decreased serum thyroid-stimulating hormone, adrenocorticotrophic hormone, and luteinizing hormone levels. These findings were consistent with evolving hypopituitarism. Contrast-enhanced magnetic resonance images revealed hemorrhage in the pituitary adenoma, suggesting pituitary apoplexy. Eight months after discontinuation of nivolumab plus ipilimumab, disease progression was noted, and nivolumab monotherapy was resumed. There was no recurrence of pituitary apoplexy during six cycles of nivolumab.

Conclusions

This case highlights that pituitary apoplexy can occur temporally after nivolumab plus ipilimumab treatment in patients with preexisting pituitary adenoma. Importantly, nivolumab monotherapy rechallenge under close monitoring may be feasible without recurrence of pituitary apoplexy.